Changeflow GovPing Pharma & Drug Safety University of Washington Muscle Gene Regulatory...
Routine Notice Added Final

University of Washington Muscle Gene Regulatory Cassettes Patent Application EP4319874A2

Favicon for changeflow.com EPO Patent Bulletin - Biotech (C12N)
Published
Detected
Email

Summary

The European Patent Office published patent application EP4319874A2 for University of Washington covering artificial regulatory cassettes for muscle-specific gene expression. The application names inventors Jeffrey S. Chamberlain and Stephen D. Hauschka. The patent is classified under IPC codes related to genetic engineering and pharmaceutical preparations for muscular disorders.

Published by EPO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

What changed

The EPO published application EP4319874A2 discloses genetic constructs designed to drive expression of therapeutic genes specifically in muscle tissue. The regulatory cassettes incorporate promoter and enhancer elements for targeted gene expression.

For parties in the biotechnology and pharmaceutical sectors, this publication establishes a public record of University of Washington's intellectual property claims in muscle-targeted gene therapy. Competitors developing similar gene expression systems should review the claims upon grant to assess potential freedom-to-operate implications.

Archived snapshot

Apr 19, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

ARTIFICIAL REGULATORY CASSETTES FOR MUSCLE-SPECIFIC GENE EXPRESSION

Publication EP4319874A2 Kind: A2 Apr 08, 2026

Applicants

University of Washington

Inventors

CHAMBERLAIN, Jeffrey S., HAUSCHKA, Stephen D.

IPC Classifications

A61P 21/00 20060101AFI20250417BHEP C12N 15/66 20060101ALI20250417BHEP C12N 15/67 20060101ALI20250417BHEP C12N 15/85 20060101ALI20250417BHEP C12N 15/861 20060101ALI20250417BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Biotech (C12N)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP4319874A2

Who this affects

Applies to
Pharmaceutical companies Clinical investigators Investors
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent applications Gene therapy research Biotechnology IP
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Biotech (C12N) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!